Hereditary Cancer Panels

Important Message from Ambry Genetics:

At Ambry, we always prioritize the quality of our testing. It is important to us that we give you the most accurate, responsible genetic testing options available.

We have heard your valuable feedback requesting lower panel turnaround times, and can now offer the same quality testing results you expect from Ambry in a much shorter period of time. Ambry is pleased to announce a turnaround time of 2-4 weeks for all “Next” hereditary cancer panels ordered on or after November 3, 2014. This applies to blood- and saliva-based testing. BRCA1/2 and BRCAplus turnaround times will remain at 7-14 days (for blood-based testing) and 9-16 days (for saliva-based testing).

At Ambry, clients and families impacted by inherited disorders are always front of mind. To make these turnaround times a reality, we have invested in more highly qualified staff (scientists, medical directors, laboratory and reporting staff, genetic counselors), cutting-edge technology, and optimized our laboratory processes. We’ve managed to achieve this without compromising the same superior quality in our lab and thoroughness in our reports you depend on when you choose to work with Ambry.

Ambry is entering a new phase, and this is just the beginning of exciting changes coming soon. We hope you’ll continue to partner with us as we continue to thoughtfully expand our testing menu and services. And we hope you’ll keep that feedback coming our way. 

Sincerely,
Ambry Genetics
 

Overview of Ambry's Technology

Hereditary Cancer Panels White Paper

Click to view Hereditary Cancer Multi-Gene Tests Table

Complete Listing of Ambry's Next Generation Hereditary Cancer Panels:

Note: Please visit each individual test page for complete details about genes included on each panel, and for panel-specific turnaround times.

 

References

1. Pennington & Swisher. Hereditary ovarian cancer: beyond the usual suspects. Gyn Onc. 2012;124:347-353. [PMID: 22264603]

2. Walsh et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. PNAS. 2010;107(28):12629-12633. [PMID: 20616022]